ETEC pilus protein chimeric PEDV spike protein multi-epitope fusion antigen and its preparation and application

By chimeric epitope of the swine epidemic diarrhea virus spike protein onto the E. coli pilin FaeG, forming a multi-epitope fusion antigen, the adhesion of the piglet diarrhea pathogen and the protectiveness of the swine epidemic diarrhea virus vaccine are solved. The problem of insufficient results has achieved efficient immune protection.

CN116478300BActive Publication Date: 2024-12-06SHANXI AGRI UNIV
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202310416372.1
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-04-17
Publication Date
2024-12-06
Estimated Expiration
2043-04-17

AI Technical Summary

Technical Problem

The prior art cannot effectively inhibit the adhesion of E. coli pili, a pathogen of diarrhea in piglets, resulting in high incidence and economic losses of diarrhea disease. At the same time, the problem of weak cross-protein protection of the swine epidemic diarrhea virus vaccine and low protein expression.

Method used

Through molecular cloning technology, the neutralizing epitope of the viral spike protein of swine epidemic diarrhea is chimeric with the enterotoxin-producing E. coli K88 piloid protein FaeG to form a multi-epitope fusion antigen to improve immunogenicity and broad spectrum.

Benefits of technology

The effective presentation of the epitope of viral spike protein in swine epidemic diarrhea virus is achieved, and specific antibodies are generated, which enhances the immune protection against pig diarrhea pathogens, and solves the problems of weak cross-protein protection and low protein expression of existing vaccines.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN116478300B_ABST
    Figure CN116478300B_ABST
Patent Text Reader

Abstract

The present invention discloses an ETEC pilus protein chimeric PEDV spike protein multi-epitope fusion antigen and its preparation and application. The fusion antigen uses the Escherichia coli K88 pilus FaeG protein as a skeleton protein and is obtained by replacing the non-neutralizing epitope on the FaeG protein with the neutralizing epitope of the PEDV spike protein. The fusion antigen prepared by the present invention effectively displays the PEDV spike protein epitope on the FaeG skeleton protein and can be recognized by porcine epidemic diarrhea virus-specific antibodies, which is of great significance for the development of a broad-spectrum multivalent vaccine for porcine diarrhea.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of multi-epitope fusion, and specifically relates to a multi-epitope fusion antigen of Escherichia coli pilus protein chimeric porcine epidemic diarrhea virus spike protein, as well as a preparation method and application of the fusion antigen. Background Art

[0002] Enterotoxigenic Escherichia coli (ETEC) is the main pathogen that causes diarrhea in piglets. It is reported that ETEC causes more than half of the deaths of piglets worldwide each year. Fimbriae (adhesins) play an important role in the pathogenicity of ETEC. ETEC mainly attaches to the intestinal epithelial cells of piglets through these fimbriae, secretes toxins, and causes diarrhea in piglets. Therefore, effectively inhibiting the adhesion of ETEC fimbriae to pig intestinal cells is the key to protecting piglets from diarrhea caused by ETEC. Studies have shown that the fimbriae of all ETEC strains isolated from piglet diarrhea are mainly F4 (K88).

[0003] Porcine epidemic diarrhea (PED) is a highly contagious enteric disease caused by porcine epidemic diarrhea virus (PEDV), with diarrhea, vomiting, and dehydration as the main clinical features. Studies have shown that the PEDV positive rate can reach 25% to 72.72%. The disease spreads very quickly. Suckling piglets under 1 week old are most susceptible to infection, with a very high morbidity rate. If not controlled in time, the mortality rate can reach 100%. There is currently no mature and effective treatment plan. In recent years, the piglet PED epidemic has spread to almost all Asian countries, causing huge economic losses. The PEDV gene is about 28kb in size, with cap structures (Cap) and Poly (A) tails at both ends. The genome contains 4 structural proteins (S protein, E protein, M protein, N protein) and 3 non-structural proteins (replicase 1a, replicase 1b and ORF3). ORF3 encodes a product with unknown function and polymorphism. S is the largest structural protein, containing neutralizing antibody epitopes and specific receptor binding sites for virus entry.

[0004] Multi-epitope chimeric recombinant fusion antigen is a vaccine technology based on neutralizing epitopes and skeleton proteins, which provides a new platform for the development of multivalent vaccines. By mimicking the natural epitopes of antigens and presenting multiple heterologous neutralizing epitopes, multi-epitope fusion antigens allow a single immunogen (protein) to carry antigenic elements (epitopes or peptides) from multiple virulence determinants, thus having a broad spectrum of immunogenicity, which is of great significance for the development of PEDV multivalent vaccines. Summary of the invention

[0005] In view of this, the present invention aims to utilize the FaeG pilus protein of enterotoxigenic Escherichia coli K88 as a skeleton protein through molecular cloning technology and spatial structure vaccine, screen its non-neutralizing epitopes and replace them with PEDV neutralizing epitopes to obtain fusion antigens, in order to solve the problems of complexity of piglet diarrhea pathogens and poor immune effect of conventional vaccines.

[0006] In order to achieve the above object, the technical solution of the present invention is as follows:

[0007] The first aspect of the present invention provides an ETEC pilus protein chimeric PEDV spike protein multi-epitope fusion antigen, which uses the FaeG pilus protein of enterotoxigenic Escherichia coli K88 as a skeleton protein, and is obtained by replacing the neutralizing epitopes of the PEDV spike protein shown in the amino acid sequences of SEQ ID NOs. 5 to 7 with the less immunogenic epitopes (i.e., non-neutralizing epitopes) on FaeG as shown in the amino acid sequences of SEQ ID NOs. 2 to 4.

[0008] In the above-mentioned ETEC pilus protein chimeric PEDV spike protein multi-epitope fusion antigen, one, two or three neutralizing epitopes can also be replaced with corresponding non-neutralizing epitopes on the backbone protein according to actual needs. In a specific embodiment of the present invention, the protein encoded by the FaeG gene sequence shown in SEQ ID NO.9 is used as the backbone, and the three PEDV spike protein neutralizing epitopes are replaced with the three non-neutralizing epitopes of FaeG respectively, and the amino acid sequence of the obtained fusion antigen is shown in SEQ ID NO.1.

[0009] It is understandable that the protein obtained by connecting a tag to the N-terminus and / or C-terminus of the amino acid sequence shown in SEQ ID NO.1, and the protein having the same function after replacing and / or deleting and / or adding one or several amino acid residues in the amino acid sequence shown in SEQ ID NO.1 still fall within the scope of protection of the present invention.

[0010] The second aspect of the present invention provides some biological materials related to the ETEC pilus protein chimeric PEDV spike protein multi-epitope fusion antigen, specifically including the following:

[0011] (i) A nucleic acid molecule (ie, gene) encoding the ETEC pilus protein chimeric PEDV spike protein multi-epitope fusion antigen;

[0012] (ii) A recombinant vector comprising the gene described in (i);

[0013] (iii). A transformant comprising the recombinant vector described in (ii).

[0014] In the above-mentioned biological material, when the amino acid sequence of the ETEC pilus protein chimeric PEDV spike protein multi-epitope fusion antigen is as shown in SEQ ID NO.1, the nucleotide sequence of its encoding gene is as shown in SEQ ID NO.8.

[0015] In the above biological materials, the recombinant vector is obtained by cloning the encoding gene into a vector, wherein the vector is preferably a pET plasmid, including but not limited to pET28a, pET30a, pET32a and the like.

[0016] In the above biological materials, the transformant is obtained by transforming the recombinant vector into a recipient cell, wherein the recipient cell is preferably Escherichia coli, including but not limited to BL21, DH5α, JM109 and the like.

[0017] The above-mentioned biological material provided by the present invention can be used to prepare ETEC pilus protein chimeric PEDV spike protein multi-epitope fusion antigen.

[0018] The third aspect of the present invention provides a method for preparing an ETEC fimbriae protein chimeric PEDV spike protein multi-epitope fusion antigen, specifically: cloning the target gene encoding the ETEC fimbriae protein chimeric PEDV spike protein multi-epitope fusion antigen into a vector, then transferring the obtained recombinant vector into a recipient cell, inducing expression, and purifying to obtain the recombinant antigen.

[0019] In the above preparation method, when the vector is a pET plasmid and the recipient cell is Escherichia coli, IPTG can be used to induce expression, and the induction conditions are preferably: 0.1-1.0 mmol / L IPTG, culturing at 16°C-37°C.

[0020] Furthermore, the purification operation is specifically as follows: collecting bacterial cells by centrifugation, disrupting the bacterial cells and collecting the precipitate, and obtaining a high-purity multi-epitope fusion protein using a denaturing buffer solution and a renaturing buffer solution.

[0021] Furthermore, the composition of the denaturation buffer is: 15-25mM PB buffer (pH 7.2-7.6), 0.4-0.6M NaCl and 7-9M urea; the composition of the refolding buffer is: 15-25mM PB buffer (pH 8.0-9.0), 4-6% glycerol, 0.04-0.06mM oxidized glutathione, 0.4-0.6mM reduced glutathione and urea, wherein the urea is 6M, 4M, 2M, 1M or 0M. The method for purifying the target protein with the refolding buffer is: the denatured target protein is placed in a dialysis bag, and the refolding buffer containing 6, 4, 2, 1 and 0 mol / L urea is used to slowly dialyze at 4°C in steps, without adding glycerol in the last two steps, and each step is dialyzed for 12-24h.

[0022] The fourth aspect of the present invention provides the use of the ETEC pilus protein chimeric PEDV spike protein multi-epitope fusion antigen prepared by the present invention, including: as an immune antigen for preparing anti-PEDV antibodies; or for preparing vaccines.

[0023] Experimental data show that the multi-epitope fusion protein provided by the present invention can effectively display the PEDV spike protein epitope on the FaeG backbone protein, and the fusion protein can specifically bind to the anti-PEDV neutralizing antibody, so it can be used as an immune antigen to prepare anti-PEDV neutralizing antibodies. Moreover, the fusion protein contains both the neutralizing epitope of the Escherichia coli pilus protein and the neutralizing epitope of the PEDV spike protein, has a broad spectrum of immunogenicity, and can be prepared into a broad-spectrum vaccine against swine diarrhea pathogens.

[0024] The beneficial effects of the present invention are as follows: the present invention uses FaeG pilus protein as a skeleton protein, which can well present the neutralizing epitope of the PEDV spike protein and can be effectively recognized by porcine epidemic diarrhea virus-specific antibodies. The obtained fusion antigen is of great significance in solving the problems of complex porcine epidemic diarrhea virus serotypes, weak cross-protection of existing vaccines, and low protein expression. BRIEF DESCRIPTION OF THE DRAWINGS

[0025] Figure 1 This is a diagram showing the Western Blotting detection results of the fusion protein in Example 3. DETAILED DESCRIPTION

[0026] In order to better understand the present invention, the content of the present invention is further explained below in conjunction with specific embodiments and drawings. It should be understood that the specific embodiments described herein are only used to illustrate and explain the present invention, and are not used to limit the present invention.

[0027] Unless otherwise specified, the examples are based on conventional experimental conditions, such as Sambrook J & Russell DW, Molecular Cloning: a Laboratory Manual, 2001, or the conditions recommended by the manufacturer's instructions. All reagents and materials used, unless otherwise specified, can be obtained from commercial sources.

[0028] Example 1 Preparation of recombinant plasmid pET28a-FaeG-PEDV

[0029] (1) Cloning of the Escherichia coli fimbriae FaeG gene and screening of its weakly immunogenic epitopes.

[0030] The enterotoxigenic Escherichia coli strain isolated from the clinic was used as a bacterial liquid template, and the pilus FaeG gene was cloned by PCR after nucleic acid extraction. The PCR reaction system is shown in the following table:

[0031]

[0032] The PCR reaction program is:

[0033]

[0034] The specific sequences of the primers in the table are:

[0035] F-EcoR I-FaeG: 5'-CGAATTCAATGAAAAAAACCCTGATC-3' (SEQ ID NO. 10);

[0036] R-XhoI-FaeG: 5'-GCTCGAGTTAGTAGTAGGTGATAGCAAC-3' (SEQ ID NO. 11).

[0037] The amplified product was recovered and sequenced as shown in SEQ ID NO. 9. After screening and verifying the epitopes of the protein encoded by the FaeG gene with weaker immunogenicity, three epitopes with weaker immunogenicity that can be replaced with the neutralizing epitope of the PEDV spike protein were provided, and their specific amino acid sequences are shown in SEQ ID NOs. 2 to 4.

[0038] (2) Construction of recombinant plasmid pET28a-FaeG-PEDV.

[0039] To screen for neutralizing epitopes with strong immunogenicity in the PEDV spike protein, in this example, the sequences shown in SEQ ID NOs. 5 to 7 were used to sequentially replace the sequences shown in SEQ ID NOs. 2 to 4 on the FaeG protein to construct a fusion protein, and the target gene encoding the fusion protein was artificially synthesized, as specifically shown in SEQ ID NO. 8.

[0040] The vector pET28a and the target gene (sequence) were double-digested, and the reaction system was as shown in the following table:

[0041]

[0042]

[0043] The digestion conditions were: 37°C, water bath digestion for 3 h.

[0044] The double-digested products were purified and recovered respectively, and then ligated using T4 ligase. The ligation reaction system is shown in the following table:

[0045]

[0046] The ligation reaction conditions were as follows: after mixing, ligation was carried out at 16°C overnight. PCR identification was performed to obtain positive monoclonal plasmids.

[0047] (3) Verification of the neutralizing epitope of PEDV spike protein.

[0048] The nucleic acid of the positive plasmid was extracted, and PCR was used to verify the existence of each neutralizing epitope, wherein the PCR reaction system is as follows:

[0049]

[0050] The PCR reaction program is:

[0051]

[0052] The sequences of the primers in the table are as follows:

[0053] F-PEDV1: 5'-TGACCGGTGACTACCATCGGTGTTTGT-3' (SEQ ID NO: 12),

[0054] R-PEDV1: 5'-CATTCCATTTGTAAGGCGCGGACCTTT-3' (SEQ ID NO: 13);

[0055] F-PEDV2: 5'-GCTAACCCCGGTTATCATCTGCTGTTCGGTCC-3' (SEQ ID NO: 14),

[0056] R-PEDV2: 5'-AACGAAGTAAGAGTTCGTCGATGTACG-3' (SEQ ID NO: 15);

[0057] F-PEDV3: 5'-ATCTTCTACGGTGGTTACTCTAACATCGGT-3' (SEQ ID NO: 16),

[0058] R-PEDV3: 5'-GTTTGGTACGGTGGACCTTTACAAAC-3' (SEQ ID NO: 17).

[0059] Example 2 Preparation of Escherichia coli pilus protein chimeric porcine epidemic diarrhea virus spike protein multi-epitope fusion protein

[0060] The positive monoclonal plasmid obtained in Example 1 was transferred into competent E. coli BL21 (DE3) cells, and after recovery, it was spread on solid culture medium for overnight culture. The next day, a single clone was picked and cultured in SB-carboxybenzyl culture medium, and IPTG (0.4mmol / L, 25°C) was added to induce overnight expression; the next day, the bacterial cells were collected by centrifugation, the cells were lysed with an ultrasonic disruptor, the precipitate was collected, and a high-purity multi-epitope fusion protein was obtained using a denaturing buffer solution and a renaturing buffer solution.

[0061] In this embodiment, the composition of the denaturation buffer solution is: 20mM PB buffer (pH 7.4), 0.5M NaCl and 8M urea, and the composition of the renaturation buffer solution is 20mM pH 8.0PB buffer, 5% glycerol, 0.05mM oxidized glutathione, 0.5mM reduced glutathione and urea (6, 4, 2, 1, 0M).

[0062] The amino acid sequence of the obtained fusion protein was shown in SEQ ID NO: 1 through amino acid sequencing analysis.

[0063] Example 3 Verification of the neutralizing epitope of FaeG-PEDV fusion protein by Western Blotting

[0064] After the FaeG-PEDV fusion protein prepared in Example 2 was separated by SDS-PAGE, the gel was rinsed with double distilled water and then transferred to the electrophoresis buffer. The PVDF membrane was placed in methanol (100%) and soaked for 30 seconds. From bottom to top, a sponge, thick filter paper, PVDF membrane, gel block, thick filter paper, and sponge were placed respectively; the assembled gel block rack was placed in the inner tank of the electrophoresis instrument, and the electrophoresis instrument was placed in a container containing an ice-water mixture to prepare for electrotransfer. The transfer parameters were: 100V, about 60 minutes. After the transfer was completed, the gel block was transferred to a tray containing gel stain; a blocking buffer (TBS, 5% skim milk) was added to the container containing the PVDF membrane so that it could cover the membrane and did not contain bubbles, and incubated at room temperature on a shaker for 1 hour. After the electroporation, the instrument, sponge, filter paper, etc. were cleaned, placed in an empty place and dried; the blocking solution was discarded, and the PVDF membrane was washed on a shaker 4 times with TBST, 5 min / time, and anti-PEDV neutralizing antibody (1:1000) diluted with 5% skim milk was added, and after removing bubbles, it was placed flat on a shaker and incubated at 4°C for 12h; the PVDF membrane was washed 5 times (TBST, 0.5% Tween-20), 5 min / time to wash away excess or non-specific binding antibodies; then goat anti-swine IgG secondary antibody (abcam, ab6753, 1:5000) was added and incubated at room temperature for 1h, and then the above-mentioned washing method was used to wash again, and the TBST rinse solution was discarded; ECL luminescent liquid (Biyuntian, P0018AS) was used for color development.

[0065] Test results such as Figure 1 As shown in the figure, Line M is a protein marker, Line 1 is the Escherichia coli FaeG pilus protein (the preparation method thereof refers to Example 1 and Example 2), and Line 2 is a recombinant protein of the FaeG backbone protein prepared in Example 2 chimeric PEDV spike protein neutralizing epitope. From the experimental results, it can be seen that the selected PEDV spike protein epitope can be displayed on the FaeG backbone protein.

[0066] The above embodiments are only for illustrating the technical concept and features of the present invention, and their purpose is to enable people familiar with the technology to understand the content of the present invention and implement it accordingly, and they cannot be used to limit the protection scope of the present invention. Any equivalent changes or modifications made according to the spirit of the present invention should be included in the protection scope of the present invention.

Claims

1. An ETEC pilus protein chimeric PEDV spike protein multi-epitope fusion antigen, characterized in that: The fusion antigen uses the FaeG pilus protein of enterotoxigenic Escherichia coli K88 as a skeleton protein, and is obtained by replacing the PEDV spike protein neutralizing epitopes with amino acid sequences such as SEQ ID NOs. 5 to 7 with the weaker immunogenic epitopes on FaeG with amino acid sequences such as SEQ ID NOs. 2 to 4, respectively; The fusion antigen is a protein having an amino acid sequence as shown in SEQ ID NO: 1, or a protein obtained by connecting a tag to the N-terminus and / or C-terminus of the sequence shown in SEQ ID NO:

1.

2. A gene encoding the ETEC pilus protein chimeric PEDV spike protein multi-epitope fusion antigen according to claim 1.

3. An expression cassette or recombinant vector comprising the gene according to claim 2. A transformant comprising the recombinant vector according to claim 3.

5. A method for preparing a multi-epitope fusion antigen of ETEC pilus protein chimeric PEDV spike protein, characterized in that: The target gene encoding the fusion antigen according to claim 1 is cloned into a vector to obtain a recombinant vector, which is then transferred into a recipient cell for induced expression and purified to obtain a recombinant protein.

6. The method for preparing the ETEC pilus protein chimeric PEDV spike protein multi-epitope fusion antigen according to claim 5, characterized in that: The vector is a pET plasmid, and the recipient cell is Escherichia coli.

Citation Information

Patent Citations

  • Soluble expression recombinant bacteria of K88 fimbria protein FaeG and fermental cultivation method thereof

    CN106119182A

  • Mucosal membrane receptor and uses thereof

    WO2009103555A2